A detailed history of Plancorp, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Plancorp, LLC holds 7,941 shares of EXEL stock, worth $276,585. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,941
Holding current value
$276,585
% of portfolio
0.01%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$21.96 - $27.6 $174,384 - $219,171
7,941 New
7,941 $206,000
Q3 2020

Nov 16, 2020

SELL
$20.67 - $26.94 $191,218 - $249,221
-9,251 Closed
0 $0
Q2 2020

Aug 11, 2020

BUY
$16.46 - $27.42 $152,271 - $253,662
9,251 New
9,251 $220,000
Q4 2019

Feb 03, 2020

SELL
$15.15 - $18.89 $191,586 - $238,882
-12,646 Closed
0 $0
Q3 2019

Nov 12, 2019

BUY
$17.68 - $22.65 $1,768 - $2,265
100 Added 0.8%
12,646 $224,000
Q2 2019

Aug 13, 2019

SELL
$18.93 - $24.75 $18,930 - $24,750
-1,000 Reduced 7.38%
12,546 $268,000
Q1 2019

May 14, 2019

BUY
$19.6 - $24.76 $32,830 - $41,473
1,675 Added 14.11%
13,546 $322,000
Q3 2017

Oct 11, 2017

BUY
$23.35 - $29.24 $277,187 - $347,108
11,871
11,871 $288,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.2B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Plancorp, LLC Portfolio

Follow Plancorp, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Plancorp, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Plancorp, LLC with notifications on news.